Login to Your Account

Astex, AstraZeneca Shape Potential $275M Agreement

By Nuala Moran

Wednesday, August 3, 2005
LONDON - Astex Therapeutics Ltd. agreed to a deal with AstraZeneca plc for a range of early stage small-molecule kinase inhibitors, securing an up-front payment of $5 million, to be followed by research and development funding, potential milestones of up to $270 million and double-digit royalties. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription